問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Neurology

Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Surgery

Division of Radiology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

陳志弘Chen, Chih-Hung
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

105Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳志弘

List

186Cases

2022-05-10 - 2026-06-30

Phase III

Active
A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)

  • Condition/Disease

    Nonsquamous Non-small Cell Lung Cancer

  • Test Drug

    注射用凍晶粉末

Participate Sites
6Sites

Recruiting6Sites

2024-05-21 - 2029-02-22

Phase III

Active
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd), A B7-H3 ANTIBODY-DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIAN’S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02)

  • Condition/Disease

    SMALL CELL LUNG CANCER (SCLC)

  • Test Drug

    injection

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2022-03-09 - 2026-12-15

Phase II

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
6Sites

Recruiting6Sites

2022-11-30 - 2027-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-03-01 - 2026-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting6Sites

2022-02-28 - 2026-12-10

Phase I/II

Active
An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

  • Condition/Disease

    Advanced Non-small Cell Lung Cancer、EGFR Mutation、HER2 Mutation

  • Test Drug

    BAY 2927088

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting2Sites

Terminated3Sites

2024-01-15 - 2029-12-31

Phase III

Active
Beamion LUNG-2: A Phase III, open-label, randomized, active- controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non- squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

  • Condition/Disease

    unresectable, locally advanced or metastatic non- squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

  • Test Drug

    Zongertinib

Participate Sites
5Sites

Recruiting5Sites

2026-04-01 - 2029-11-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2025-10-01 - 2035-01-20

Phase III

Not yet recruiting
Beamion LUNG-3: A randomized, controlled, multicenter study evaluating zongertinib as adjuvant monotherapy versus standard of care in patients with early-stage, resectable non-small cell lung cancer (stage II–IIIB) harboring activating HER2 mutations in the tyrosine kinase domain.

  • Condition/Disease

    Early, resectable non-small cell lung cancer (stage II to IIIB) with HER2 mutations involving activating alterations in the tyrosine kinase domain

  • Test Drug

    Injection Film-coated tablet Injection Injection Injection

Participate Sites
6Sites

Recruiting6Sites

2023-11-01 - 2025-12-31

Phase II

Completed
DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas

  • Condition/Disease

    Small Cell Lung Carcinoma、 Neuroendocrine Neoplasms 、Extra-pulmonary Neuroendocrine Carcinoma

  • Test Drug

    N/A

Participate Sites
3Sites

Terminated3Sites

1 9 10 11 12 13 19
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB